Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer

Anticancer Research

Volumn 28, Issue 2 A, 2008, Pages 949-955

  Neubauer, Hans ^a,c   Stefanova, Maya ^a   Solomayer, Erich ^a   Meisner, Christoph ^b   Zwirner, Manfred ^a   Wallwiener, Diethelm ^a   Fehm, Tanja ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c NONE   (Germany)

Author keywords

ATP; Chemosensitivity; Drug resistance; Ovarian cancer; Prediction

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; PLATINUM;

ADENOSINE TRIPHOSPHATE TUMOR CHEMOSENSITIVITY ASSAY; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOASSAY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; LOGISTIC REGRESSION ANALYSIS; MULTIVARIATE ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UNIVARIATE ANALYSIS;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DRUG EVALUATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 42549106829     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
2. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton ICD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B and Pecorelli S: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699-708, 2000.
3. Sevin BU, Perras JP, Averette HE, Donato DM and Penalver M: Chemosensitivity testing in ovarian cancer. Cancer 71: 1613-1620, 1993.
4. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Marmel RS, DeGeest K, Hartenbach EM and Baergen R; Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200, 2003.
5. Sevin BU, Peng ZL, Perras JP, Ganjei P, Penalver M and Averette HE: Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol 31: 191-204, 1988.
6. Kurbacher CM, Cree IA, Bruckner HW, Brenne U, Kurbacher JA, Muller K, Ackermann T, Gilster TJ, Wilhelm LM, Engel H, Mallmann PK and Andreotti PE: Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 9: 51-57, 1998.
7. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleibermann I, Caruso PA, Ricks SH, Untch M, Sartori C and Bruckner HW: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55: 5276-5282, 1995.
8. Geisler JP, Linnemeier GC, Thomas AJ and Manahan KJ: Extreme drug resistance is common after prior exposure to paclitaxel. Gynecol Oncol 106: 538-540, 2007.
9. http://www.ago-ovar.de/leitlinien/leitlinien.html
10. Konecny G, Crohns C, Pelgram M, Felber M, Lude S, Kurbacher C, Cree IA, Heep H and Untch M: Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 77: 258-263, 2000.
11. Sharma S, Neale MH, Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, Higgins BR, Lamont A, Osborne R, Hindley AC, Kurbacher CM and Cree IA: Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 3: 19-28, 2003.
12. Kleinbaum DG, Kupper LL and Morgenstern H: Epidemiologic Research. Lifetime Learning. California, Publications Belomont, p. 299, 1982.
13. Andreotti PE, Linder D, Hartmann OM, Johnson LJ and Harel GA: ATP lymphocyte activation assay: application for lymphokines and cytokines. In: Bioluminescence and Chemiluminescence: Current Status. Szalay AA, Stanley PE and Kircka LJ (eds.). Chichester, John Wiley & Sons, pp. 257-261, 1993.
14. Kern DH and Weisenthal LM: Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 82: 582-588, 1990.
15. Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, Hosford S, Schellhas H, Wells A and Sevin BU: Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 16: 194-201, 2006.
16. Cree IA, Kurbacher CM, Untch M, Sutherland LA, Huner EM, Subedi AM, James EA, Dewar JA, Preece PE, Andreotti PE and Bruckner HW: Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs 7: 630-635, 1996.
17. Gerhardt RT, Perras JP, Sevin BU, Petru E, Ramos R, Guerra L and Averette HE: Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay. Am J Obstet Gynecol 165: 245-255, 1991.
18. Di Nicolantonio F, Neale MH, Knight LA, Lamont A, Skailes GE, Osborne RJ, Allerton R, Kurbacher CM and Cree IA: Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer. Anticancer Drugs 13: 625-630, 2002.
19. Neale MH, Lamont A, Hindley A, Kurbacher CM and Cree IA: The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma. Anticancer Drugs 11: 865-871, 2000.
20. O'Meara AT and Sevin BU: Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol 83: 334-342, 2001.
21. Chrenek MA, Wong P and Weaver VM: Tumour-stromal interactions. Integrins and cell adhesions as modulators of mammary cell survival and transformation. Breast Cancer Res 3: 224-229, 2001.
22. Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H and Tashiro S: Tumor stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28: 38-44, 2004.
23. Andjilani M, Droz JP, Benahmed M and Tabone E: Down-regulation of FAK and IAPs by laminin during cisplatin-induced apoptosis in testicular germ cell tumors. Int J Oncol 28: 535-542, 2006.